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THE influence  of  an  anti-allergic  agent,  suplatast
tosilate  (IPD–1151T;  (±)-[2-[4-(3-ethoxy–2-hydroxy-
propoxy)phenyl-carbamoyl]-ethyl]  dimethylsulfon-
ium p-toluenesulfonate) on allergic bronchoconstric-
tion  induced  by  allergen  and  methacholine  (MCh )
were examined in mice. BALB/c mice were sensitized
by  intraperitoneal  injection  of  dinitrophenylated-
keyhole limpet hemocyanin (DNP-KLH) mixed with
Al(OH)3 (DNP-KLH).  IPD–1151T  was  administered
orally once a day for either 5 or 14 days in doses of 10,
30 or 100 mg/kg. Bronchoconstriction was measured
24h after the final drug  administration.  IPD–1151T
inhibited both antigen- and MCh-mediated broncho-
constriction in actively sensitized mice.  The inhibi-
tion  induced  was  closely  related  to  the  dose  and
frequency of oral administration of the agent. We also
examined the effect of IPD–1151T on IgE production
in response to DNP–KLH immunization.  IPD–1151T
inhibited dose-dependently both total and specific IgE
concentrations in serum prepared from mice 15 days
after  immunization.  These  results  strongly  indicate
that  IPD–1151T inhibits IgE  production in vivo and
results in attenuating effect on bronchoconstriction.
Key words: Anti-allergic agent, Allergen, Bronchoconstric-
tion,  IgE,  IL–4,  IPD–1151T,  Methacholine,  Mouse,
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Introduction
Bronchial hyper-responsiveness (BHR) is an important
feature of bronchial asthma and the degree of BHR is
believed to reflect the severity of the disease.1,2 The
ultimate  task  of  asthma  treatment  is  the  relief  of
symptoms to permit a normal style of life. The main
measures  to  achieve  this  focus  on  the  decrease  of
airflow obstruction and the shift of BHR towards a
normal  range.3,4 To  accomplish  these  objectives,
several types of anti-allergic drugs with bronchodilat-
ing activity have been developed and are used in the
treatment  and  management  of  bronchial  asthma.
Although  the  mechanisms  of  BHR  are  not  fully
understood, there is an established concept that IgE is
a prime mediator in development of BHR, especially
allergen-induced BHR.4–7 That is, IgE antibodies bind
to  specific  membrane  receptors  on  mast  cells  and
basophils.  Combination  of  specific  cell-bound  anti-
body with antigen triggers a series of events leading
to release of vasoactive amines and other pharmaco-
logically  active  substances  responsible  for  clinical
manifestation of BHR.8 Recently IgE antibody recep-
tors have also been demonstrated on a subpopulation
of eosinophils and platelets, among others.9 Binding
of IgE antibody to receptors on these cells results in
the enhancement of their function and the release of
various  chemical  mediators  responsible  for  allergic
inflammation.10–12 From  these  standpoints,  drugs
specifically inhibiting IgE antibody formation would
be highly feasible for the therapy of allergic patients.
However, such drugs are not available nowadays.
During immunopharmacological  studies  on  dime-
thylsulfonium compounds, it  is found that  suplatast
tosilate  (IPD–1151T)  suppresses Th2  type  cytokine
production,  IgE  synthesis,  and  chemical  mediator
release from mast cells in the mouse and guinea pig
models  of  asthma.13–17 IPD–1151T  has  also  been
reported  to  suppress  the  production  of  Th2  type
cytokines and IgE by human peripheral blood leuko-
cytes when the cells were obtained from asthmatic
patients  and  cultured  with  specific  antigens  in  the
presence of the agent.18,19 Furthermore, it is observed
that oral administration of IPD–1151T could attenuate
eosinophilia  and  hyperimmunoglobulinemia  E  in
patients with Kimura’s disease.20 From these reports,
there is a possibility that IPD–1151T may be a new anti-
allergic drug that could prove useful for treatment and
prevention of asthma. However, there are no reports of
the influence of IPD–1151T on bronchoconstriction.
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Specific  pathogen-free,  normal and  athymic  BALB/c
mice were purchased from Charles River Japan Inc.,
Atsugi, Japan. They were all male and 5 weeks of age
at the start of the experiments. Conventional Wistar
male  rats  were  obtained  from  Nippon  Bio-supply
Center (Tokyo, Japan). All animal experimental proce-
dures used in this study were approved by the Showa
University Animal Ethics Committee, and carried out
in accordance with the guidelines of the Physiological
Society of Japan.
Agent
IPD–1151T (Fig. 1) was kindly supplied from Taiho
Pharmaceutical  Co.  Ltd.,  Tokyo,  Japan,  as  a  pre-
servative-free pure powder. The agent was dissolved
in distilled water at 5 mg/ml just before use.
Antigens
KLH (Sigma Chemical Co. Ltd, St Louis, MO, USA) was
coupled with dinitrobenzen-sulfonic acid sodium salt
(DNP) (Tokyo Kasei Corp., Tokyo, Japan) according to
the  methods  of  Lee  and  Sehon.21 Bovine  serum
albumin  (BSA)  (Sigma  Chemical  Co.  Ltd.)  was  also
coupled  with  DNP  in  a  similar  manner. They  were
abbreviated DNP-KLH and DNP-BSA, respectively.
Preparation of cell suspension
To  prepare  spleen  cell  suspension,  normal  BALB/c
mice  were  killed  by  intraperitoneal  injection  with
pentobarbital sodium (Abbott Lab., North Chicago, IL,
USA) at a dose of 60 mg/kg. The spleen was removed,
pooled  from  five  mice  and  stored  at  4°C  until
processed.  The  organs  were  pressed  through  a
60-gauge  steel  mesh  and  then  filtered  through  a
200-gauge  steel  mesh  to  remove  debris  and  cell
clumps. The cells were washed five times with RPMI–
1640  medium  (Flow  Lab.,  Irvine,  Scotland)  supple-
mented with 10% fetal calf serum (FCS) (Flow Lab.,
North Ride, Australia), 5 ´ 10–5 M 2 mercaptoethanol,
10 mM  N-2-hydroxyethylpiperazine-N’-2-ethane-
sulfonic  acid,  100 U/ml  penicillin  and  100 m g/ml
streptomycin  (RPMI-FCS)  and  resuspended  in  the
fresh medium at a concentration of 5 ´ 106 cells/ml.
Spleen cell suspensions were also prepared from five
athymic nude mice in a similar manner.
Cell culture
Spleen cell suspension (100 m l) was introduced into
each  well  of  96-well  flat-bottomed  microculture
plates (Nunc Intermed, Denmark), which contained
10 m g/ml of either lippoporisaccharide (LPS) or con-
canavalin A  (Con A). The plats were maintained for
48 h in a humidified atmosphere with 5% CO2 at 37°C.
Cell activation was assessed by adding 1 m Ci/well of
3H-thymidine  (Amersham  International  plc,  Bucks,
UK)  for  the  final  6h  of  culture. The  results  were
expressed as mean cpm ± SD of triplicate cultures. To
prepare  culture  supernatant,  1 ml  of  spleen  cell
suspension  was  cultured  in  24-well  culture  plates
(Nunc Intermed) containing 1 ml of 10 m g/ml of Con
A. After 24h, culture supernatants were obtained after
pelleting  the  cells  by  centrifugation  at  2000 g for
10 min at 4°C. The supernatant was stored at –40°C
until used.
Immunization
Mice  were  immunized  by  intraperitoneal  injection
with  5 m g/ml  of  DNP-KLH  mixed  with  2 mg  of
Al(OH)3 (Wako Pure Chemical Ind., Osaka, Japan) in a
total volume of 0.5 ml of saline.
Drug administration
Mice were orally administered with either 10, 30 or
100 mg/kg of IPD–1151T in a volume not exceeding
0.5 ml. Administration was performed once a day on
the  following  schedules:  one  group  of  mice  were
treated for 5 days from Day 9 of sensitization and the
others for 14 days from Day 0. Control mice received
distilled  water  only  in  a  volume  not  exceeding
0.5 ml.
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FIG. 1. Chemical structure of suplatast tosilate (IPD–1151T).Assay for IgE antibody
Mice  were  bled  by  cardiac  puncture.  Serum  was
isolated by centrifugation and stored at –40°C until
used. Total  concentration  of  IgE  antibody  in  serum
was  assayed  by  commercially  prepared  mouse  IgE
enzyme-linked immunosorbent assay (ELISA) test kit
(Yamasa  Shoyu Co. Ltd,  Chiba,  Japan) according to
the manufacturer’s recommended procedure. Briefly,
wells  of  a  96-well  microtiter  plate  coated  with
antimouse IgE monoclonal antibody received 100 m l
of  test  samples  and  of  standards,  separately.  After
incubation at 25°C for 30 min, the wells were washed
5 times with washing buffer. Antimouse IgE enzyme
conjugate  (100 m l/well)  was  then  introduced  into
each well and further incubated for 30 min at 25°C.
After washing, 200 m l of substrate, tetramethylbenzi-
dine, was dispensed, and the reaction proceeded at
25°C  for  15 min. Absorbance  at  450 nm  was  deter-
mined with an ELISA reader (MRP A4i) (Tosoh Co. Ltd,
Tokyo, Japan) after adding 50 m l of 2N HCl. The ELISA
was  performed  in  duplicate  and  mean  absorbance
was  obtained.  Serum antibody  concentrations  were
calculated from standard curve and the results were
expressed as mean ng/ml ± SE of five individual mice.
The  concentration  of  DNP-specific  IgE  antibody  in
serum was assayed by passive cutaneous anaphylaxis
(PCA) in Wistar rats. An intradermal injection of 0.1 ml
of serum dilutions was given on the shaved back of
rats. Sensitized rats were challenged by 1 mg of DNP-
BSA in 1ml of 0.5% Evans blue dye. Reciprocals of the
highest  dilution  were  recorded  as  the  titer  of  the
specific IgE antibody. The results were expressed as
the mean PCA titer ± SE of five individual samples.
Assay for IL-4
IL-4 contents in culture supernatants was assayed by
the  commercially  available  mouse  IL-4  ELISA  kit
(GENZYME TECHNE  Corp., Minneapolis,  MN,  USA)
according  to  the  manufacturer’s  recommendation.
The ELISA was done in duplicate and the results were
expressed  as  mean  pg/ml  ±  SE  of  five  individual
mice.
Measurement of airway reactivity
Twenty-four hours after the final drug administration,
mice were anesthetized with intraperitoneal injection
of  1.8 mg/kg  body  weight  of  pentobarbital  sodium
(Abbott  Lab.). When  an  appropriate  plane  of  anes-
thesia was induced, the trachea was cannulated and
connected to a constant-volume respirator for small
animals  (SN–480–3;  Shinano  Seisakusho,  Tokyo,
Japan) that provided ventilation at a tidal volume of
0.5 ml/100 g  body  weight and a  rate  of  60  strokes/
min.21 Under these conditions, we found that arterial
oxygen tension of the mice was kept between 70 and
80  torr  as  measured  with  a  transcutaneous  oxygen
tension  meter  (OXV–7101)  (Nihon  Koden  Co.  Ltd,
Tokyo,  Japan). The  flow  at  the  outlet  of  the  intra-
tracheal  cannula  was  measured  using  a  differential
transducer (TP–602) (Nihon Koden Co. Ltd). One end
of  the  differential  pressure  was  connected  to  the
outlet of the tracheal cannula, the  other end being
exposed  to  atmospheric  pressure.  The  respiratory
resistance was determined by the method of Konzett
and Rossler22 from transpulmonary pressure, airflow
and respiratory volume measures. Airway responses
to KLH were measured by intravenous administration
of 500 m g/ml of KLH in a volume of 0.1ml.21 In the
case  of  examining  the  influence  of  a  bronchocon-
strictor  agonist  on  airway  responses,  mice  were
injected  intravenously  with  increasing  quantities  of
MCh (10–6 M to 10–2 M) in  a volume of 0.1 ml. The
results were expressed  as mean volume (ml)  of  air
overflow ± SE of five mice.
Statistics
Statistical  significance  was  determined  by  Mann–
Whitney U-test.
Results
Influence of IPD–1151T on airway
hyper-responsiveness
The first set of experiments was designed to examine
the influence of IPD–1151T on airway hyper-respon-
siveness. To do this, we examined firstly the minimum
concentration  of  MCh  that  can  cause  significant
Suppression of bronchoconstriction by IPD
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FIG. 2. Influence of MCh on bronchial responsiveness in non-
sensitized  mice. Each  data item is  the mean  ±  SE  of  five
mice.bronchoconstriction in non-sensitized mice. The data
are  shown  in  Fig.  2. Although  low  doses  of  MCh
(10–6 M and 10–5 M) scarcely affected airway respon-
ses, significant (P<0.05) increase in airway overflow
was observed when mice were injected intravenously
with  10–4 M  MCh.  The  next  experiments  were
designed to examine the influence of oral administra-
tion of IPD–1151T on MCh-induced bronchoconstric-
tion in DNP-KLH-sensitized mice. As shown in Fig. 3,
intravenous administration of 10–4 M MCh into sensi-
tized  mice  caused  a  significant  increase  in  airway
hyper-responsiveness  as  compared  with  non-sensi-
tized control (P<0.001). Oral administration of IPD–
1151T  inhibited  MCh-induced  increase  in  airway
responses.  The  minimum  effective  dose  in  5-day
treatment was 100 mg/kg and that in 14-day treatment
was  10 mg/kg.  The  influence  of  IPD–1151T  on
antigen-induced allergic airway responses is shown in
Fig. 4. KLH in sensitized mice caused a strong allergic
bronchoconstriction as compared with non-sensitized
control (P<0.001). Oral administration of IPD–1151T
inhibited  allergic  bronchoconstriction  in  a  dose-
dependent fashion: as dose and frequency of admin-
istration  were  increased,  volume  of  air  overflow
gradually decreased (Fig. 4).
Influence of IPD–1151T on in vivo IgE
production
BALB/c  mice  were  sensitized  intraperitoneally with
DNP-KLH.  Immune  serum  was  obtained  from  five
individual mice 7, 10, 14, 17, 21 and 25 days after
sensitization. Non-immune serum was also obtained
from age-matched, non-sensitized mice. As shown in
Fig.  5A,  total  IgE  concentration  in  immune  serum
gradually increased, peaked on Day 14 and declined
thereafter from Days 17 to 25. Changes in the levels of
DNP-specific IgE antibody showed a similar pattern to
that observed in total IgE concentration: the specific
antibody was first detected on Day 7, peaked on Day
14  and  declined  control  levels  from  Day  17,  but
sustained on Day 25 (Fig. 5B). The influence of oral
administration of IPD–1151T on total and specific IgE
concentration  in  serum  prepared  from  mice  sensi-
tized with DNP-KLH is shown in Fig. 6. Oral admin-
istration of IPD–1151T, starting on Day 9 of sensitiza-
tion, significantly inhibited both total and specific IgE
concentration in serum obtained 15 days after sensiti-
zation (P<0.05; Fig. 6). This inhibitory action of IPD–
1151T on was further strengthened when administra-
tion  of  agent  was started on  Day 0  of  sensitization
(Fig. 6).
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FIG. 3. Influence of suplatast tosilate (IPD–1151T) on MCh-mediated allergic bronchoconstriction in actively sensitized BALB/c
mice. Mice were sensitized by intraperitoneal injection with DNP-KLH. The mice were administered orally with IPD–1151T for
either 5 (starting on Day 9) (j ) or 14 (starting on Day 0) ( ) days from the day of sensitization. Airway responses to 10
–4 M MCh
injected  intravenously  were  measured  on  Day  15,  24h  after  the  final  drug  administration. This  is  one  of  two  different
experiments which gave reproducible results. N.S., Not significant.Influence of IPD–1151T on in vitro lymphocyte
proliferative response and interleukin (IL)–4
production
Influence of IPD–1151T on proliferative activities of
spleen cells in  response to mitogenic stimulation  is
shown in Table 1. IPD–1151T inhibited cell prolifera-
tion in dose-dependent manner when the cells were
prepared from nude mice and stimulated with LPS in
vitro. However, IPD–1151T could not suppress T cell
mitogen  (Con  A)-induced  proliferative  response  of
spleen cells prepared from normal mice even when
the cells were cultured in the presence of 100 m g/ml
Suppression of bronchoconstriction by IPD
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FIG. 4. Influence of suplatast tosilate (IPD–1151T) on bronchoconstriction induced by allergen in actively sensitized BALB/c
mice. Mice were sensitized by intraperitoneal injection with DNP-KLH. The mice were administered orally with IPD–1151T for
either 5 (starting on Day 9) (j ) or 14 (starting on Day 0) ( ) days from the day of sensitization. Airway responses to 500 m g of
KLH injected intravenously were measured on Day 15, 24h after the final drug administration. This is one of two different
experiments which gave reproducible results
FIG. 5. Changes in total (A) and specific (B) IgE concentrations in serum prepared from BALB/c mice sensitized with DNP-KLH.
The mice  were injected intraperitoneally with 5 m g  of  DNP-KLH  mixed with  Al(OH)3 and serum  was prepared from  five
individual mice. Each data item is the mean ± SE of one of three different experiments which gave reproducible results. (h )
Non-sensitized mice; (j ) sensitized mice.of  the  agent.  IL–4  production  by  spleen  cells  in
response  to  Con  A  stimulation  in  vitro was  sig-
nificantly  inhibited  by  IPD–1151T.  This  inhibitory
effect on IL–4 production was dose-dependent  and
first noted at  a concentration of as little as 5 m g/ml
(Table 2).
Discussion
The  present  study  shows  that  IPD–1151T  inhibits
MCh-induced  increase  in  airway  responses  in  pre-
sensitized mice. IPD–1151T has an ill-defined mode
of action, and various elements could account for this
protective  effect.  Functional  antagonism  towards
MCh-induced  bronchoconstriction  does,  however,
not  account  for  the  findings  in  the  present  study,
since  the  MCh  responsiveness  in  normal  control
animals  is  not  altered  (Fig.  3).  It  is  reported  that
mouse  has  airway  contractile  tissue  that  responds
when exposed to muscarinic agonists such as MCh by
the  vascular  route.23 There  is  also  evidence  that
airway response to muscarinic agonists is presumably
K. Asano et al.
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FIG. 6. Influence of IPD–1151T on total (A) and specific (B) IgE concentrations in serum prepared from BALB/c mice sensitized
with DNP-KLH. All mice were injected intraperitoneally with 5 m g of DNP-KLH mixed with Al(OH)3. The mice were administered
orally with IPD–1151T for either 5 (starting on Day 9) (j ) or 14 (starting on Day 0) ( ) days from the day of sensitization. Serum
was prepared from five individual mice on Day 15, 24h after final drug administration.
Table 1. Influence of IPD–1151T on blastic activity of spleen










0 25.5 ± 0.5 79.6 ± 1.3
5 16.5 ± 2.0 85.0 ± 5.3
10 14.3 ± 0.2 71.9 ± 14.7
50 9.4 ± 0.2 76.7 ± 1.6
100 6.4 ± 0.1 82.2 ± 2.2
a Spleen cells were prepared from normal (+/+) and athymic nude (–/–)
mice,  and  used  as  target  cells  for  LPS  and  Con  A  stimulation,
respectively. Cells (5 ´ 105 cells/200 m l) were cultured in triplicate in
the presence of 5 m g of mitogens for 48h.
Table 2. Influence of IPD–1151T on in vitro IL–4 production





(mean pg/ml ± SE)
Reduction
(%)
0 214.7 ± 10.4
5 186.9 ± 27.1* 30.4
10 127.9 ± 16.1** 40.4
50 128.3 ± 7.9** 40.2
100 109.1 ± 12.5** 49.2
500 68.2 ± 12.2** 68.2
a Spleen  cells (5 ´ 106 cells/ml) prepared from five  normal BALB/c
mice were cultured with 10 m g/ml Con A for 24h. IL–4 contents in
culture supernatants were assayed by ELISA.
*Not  significant  (P>0.05)  as  compared  with  control,  **Significant
(P<0.01) as compared with control.mediated  by  specific  muscarinic  receptor  activa-
tion.24Therefore, the data in Fig. 3 may be interpreted
as  showing  that  IPD–1151T  inhibits  muscarinic
receptor  activation  that  is  induced  by  sensitization
with DNP-KLH and results in therapeutic effects on
KLH-induced increase in airway response to MCh.
The  importance  of  IgE-related  reactions  in  terms
of their ability to influence airway function has been
apparent  from  clinical  and  experimental  studies.
Sensitization of mice by inhalation of allergen caused
not  only  IgE  hyper-production  but  also  increased
airway  reactivity.4,5 Histological  examination  of  the
nose  and  lungs  including  lower  and  upper  airways
prepared from sensitized mice revealed  an  absence
of neutrophils, eosinophils and mast cells at the time
of  the  increased airway hyper-responsiveness.4 It  is
also reported that passively transferred rabbit serum
containing allergen-specific IgE is capable of sensitiz-
ing  naive  rabbits  so  that  they  develop  airway
obstruction,25 as  well  as  increased  airway  hyper-
responsiveness  after  exposure  to  specific  aller-
gen.26,27 These  reports  strongly  suggest  that  altera-
tions  in  airway  function  such  as  hyper-
responsiveness to allergens are closely linked to the
presence of  allergen-specific IgE. The present  study
revealed  the  inhibitory  effect  of  IPD–1151T  on
levels of both total and specific IgE when the mice
were administered orally with the agent (Fig. 6). It is
also showed that inhibitory effect of IPD–1151T on
IgE  production  is  due  to  its  suppressive  action  on
B-cell  proliferation  (Table  1)  and  IL–4  production
from  T-cells  (Table  2).  Taken  together,  a  second
possible  explanation  for  the  protective  effect  of
IPD–1151T on antigen-induced airway hyper-respon-
siveness  (Fig.  3)  would  be  an  effect  on  IgE
production.
Upon antigenic stimulation, cross-linking of surface
IgE bound to receptors expressed on mast cells and
basophils  caused  secretion  of  substances  stored  in
granules  such  as  histamine  and  serotonin,  etc.28,29
and newly produced physiologically active substances
such as leukotrien and platelet activating factor.30,31
These  chemical  mediators  are  reported  to  provoke
alteration of smooth muscle in airways and result in
bronchoconstriction.32,33 Matsuura  et  al.15 revealed
the inhibitory action of IPD–1151T on degranulation
of mast cells in response to antigenic stimulation in
vitro. From these observations, there is a possibility
that IPD–1151T  may function as a membrane stabi-
lizer and attenuate bronchoconstriction induced  by
MCh and specific antigen.
Since  mice  administered  IPD–1151T  for  14  days
(100 mg/kg/day) did not show weight loss, ruffled fur
and a hunched posture, compared with the control,
IPD–1151T could be expected to develop into a new
anti-asthmatic drug.
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